US 12,281,113 B2
Crystalline forms of a KRas G12C inhibitor
Patricia Andres, San Diego, CA (US); Samuel Andrew, Cambridge (GB); Cheng Yi Chen, San Diego, CA (US); Susana Del Rio Gancedo, Cambridge (GB); Tawfik Gharbaoui, Escondido, CA (US); and Jennifer Nelson, West Lafayette, IN (US)
Assigned to MIRATI THERAPEUTICS, INC., Princeton, NJ (US)
Filed by MIRATI THERAPEUTICS, INC., San Diego, CA (US)
Filed on Jul. 24, 2024, as Appl. No. 18/782,879.
Application 18/782,879 is a continuation of application No. 18/025,817, previously published as PCT/US2021/049940, filed on Sep. 10, 2021.
Claims priority of provisional application 63/093,673, filed on Oct. 19, 2020.
Claims priority of provisional application 63/077,553, filed on Sep. 11, 2020.
Prior Publication US 2024/0376107 A1, Nov. 14, 2024
Int. Cl. C07D 471/04 (2006.01); A61P 35/00 (2006.01)
CPC C07D 471/04 (2013.01) [A61P 35/00 (2018.01); C07B 2200/13 (2013.01)] 30 Claims
OG exemplary drawing
 
1. Crystalline Form A of 2-[(2S)-4-[7-(8-chloro-1-naphthyl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile, having an X-ray powder diffraction pattern comprising at least one peak at °2θ selected from 8.6±0.2, 14.6±0.2, 16.9±0.2 and 18.3±0.2.